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Chronic infl  ammation caused by infectious or 
autoimmune diseases is clearly associated with 
increased cancer risk. It has been estimated that 
chronic infl  ammation contributes to the devel-
opment of  15% of malignancies worldwide (1) 
and postulated that it promotes tumor growth, 
in part, through stimulation of angiogenesis. 
Chronic infl  ammation results in up-regulation 
of various cytokines, including IL-1α/β, IFN-γ,
and TNF-α in infl   ammatory cells. Because 
these nonspecifi  c proinfl  ammatory cytokines 
induce expression of proinfl  ammatory media-
tors, including cyclooxygenase-2 (COX-2) and 
proinfl  ammatory chemokines (2–4), we sought 
to determine whether there was a connection 
between COX-2 and chemokine signaling 
pathways in colorectal cancer (CRC).
Prostaglandin E2 (PGE2) plays a role in pro-
moting progression of CRC. PGE2 levels are 
elevated in human CRCs and adenomas in 
  familial adenomatous polyposis patients (5–8). 
We have previously shown that PGE2 acceler-
ates intestinal adenoma growth in ApcMin mice 
(9). PGE2 is thought to mediate the eff  ect of 
COX-2 during angiogenesis because treatment 
with PGE2 reversed the anti-angiogenic eff  ects 
of a selective COX-2 selective inhibitor (10). 
However, the mechanism(s) by which PGE2 
contributes to tumor-associated angiogenesis 
and modulates endothelial cell biology remains 
unclear. Therefore, we tested the hypothesis 
that PGE2, a proinfl  ammatory mediator, stimu-
lates colon carcinoma cells to produce angio-
genic factors that modulate endothelial cell 
migration and tube formation.
Chemokines are known to play a major role 
in regulating infl  ammation and wound healing. 
Growth-regulated oncogene (GRO) is a member 
of the CXC chemokine family that is crucial for 
the recruitment of neutrophils to infl  ammatory 
sites. Three distinct GRO isoforms (α, β, and γ) 
have been isolated, characterized, and now are 
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referred to as CXCL1, CXCL2, and CXCL3, respectively. All 
three ligands bind to the CXC chemokine receptor CXCR2, 
with CXCL1 (GROα) having the highest affi   nity (11). The 
CXCL1 gene was fi  rst identifi  ed by subtractive hybridization 
from tumorigenic versus nontumorigenic Chinese hamster em-
bryonic fi  broblasts (12), and the CXCL1 protein was originally 
purifi  ed as an autocrine growth factor from supernatants of a 
human melanoma cell line (13, 14). The mouse CXCL1-3 ho-
mologues macrophage infl  ammatory protein (MIP)-2 and KC 
have also been cloned (15, 16). CXCL1 is expressed at high 
levels constitutively in melanoma and in several disorders that 
involve acute and chronic infl  ammation. For example, CXCL1 
is expressed in 70% of the human melanomas, but very low lev-
els of CXCL2 (GROβ) or CXCL3 (GROγ) are found in these 
tumors (17). Overexpression of CXCL1 in immortalized mela-
nocytes results in cell transformation (18). Furthermore, this 
chemokine is a potent mediator of tumor-associated angiogen-
esis in Kaposi’s sarcoma and non-small cell lung cancer (19–21). 
However, the role of CXCL1 in CRC has not been reported.
To examine tumor-associated angiogenesis in vivo, we 
generated the Rag2(−/−)/γc(−/−)/Flk1(+/−)lacZ triple mutant 
mice. These triple mutant mice serve as a powerful tool to 
examine human tumor-associated angiogenesis by exploiting 
β-galactosidase activity in endothelial cells as a marker for Flk1 
promoter activity and a measure of angiogenesis. We investi-
gated whether PGE2 could regulate tumor-associated angiogen-
esis by causing tumor cells to produce pro-angiogenic factors.
Here we report that CXCL1 mRNA and protein expression 
Figure 1.  CXCL1 expression is elevated in human colorectal tumors 
and adenomas of Apcmin mice. CXCL1 expression is associated with PGE2 
levels. The CXCL1 expression in 20 tumors and the matched normal tissues 
is measured by quantitative real-time PCR (A) and ELISA (B), and the levels 
of PGE2 in these tissues were quantifi  ed using gas chromatography nega-
tive ion chemical ionization mass spectrometry (C). The levels of MIP-2 
(D) and KC (E) mRNA in the normal and intestinal adenoma tissues from 
six Apcmin mice were also analyzed by quantitative real-time PCR. The 
relative expression of target gene is averages of triplicates that are nor-
malized against the transcript levels of h-β-actin or mGAPDH. Data are 
represented as the mean ± SE of the relative expression from six mice. 
  Asterisks represent statistical differences (P < 0.05; Student’s t test).JEM VOL. 203, April 17, 2006  943
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is elevated in 85 and 65% of human CRCs, respectively, and 
correlates well with PGE2 levels in CRC tissues. We also 
demonstrate that exogenous PGE2 induces CXCL1 expres-
sion and release in CRC cells in vitro and in vivo. Induction 
of CXCL1 by PGE2 is dose dependent and involves activa-
tion of the epidermal growth factor receptor (EGFR)–mito-
gen-activated protein kinase (MAPK) pathway. Furthermore, 
we found that the conditioned medium from PGE2-treated 
CRC cells enhanced endothelial cell migration and tube for-
mation, and that CXCL1 released from CRC cells mediates 
PGE2-induced endothelial cell migration and tube formation 
in vitro. The in vitro eff  ect of PGE2 on endothelial cells via 
CXCL1 stimulation was confi  rmed in vivo. Treatment with 
an anti-CXCL1–neutralizing antibody resulted in a reduction 
of tumor growth with decreased microvessel formation. These 
results demonstrate that PGE2-induced CXCL1 expression is 
involved in CRC tumor growth and angiogenesis.
RESULTS
CXCL1 expression correlates with PGE2 levels in human CRC
Because CXCL1 is highly expressed in human melanomas, 
we determined whether CXCL1 levels are also increased in 
human CRCs. Real-time quantitative PCR and ELISA as-
says were performed to measure CXCL1 levels in human co-
lon carcinomas at grade II–III compared with the matched 
normal tissues. CXCL1 mRNA levels were elevated in 17 of 
20 (85%) cancer specimens (Fig. 1 A). CXCL1 protein ex-
pression was also elevated in 13 of 20 (65%) cancer specimens 
and was undetectable in 13 matched normal tissues (Fig. 1 B, 
see pairs 1, 2, 5, 6, 7, 8, 9, 13, 14, 15, 17, 19, and 20). In 
paired samples 3, 10, 12, and 18, the CXCL1 was not de-
tected. Because diff  erences in CXCL1 levels were less than 
twofold in pairs 4, 11, and 16, these changes were not con-
sidered signifi  cant. CXCL1 mRNA and protein levels corre-
late well in these human biopsies (Fig. 1, A and B). It has 
been established that PGE2 levels correlate well with progres-
sion of human colorectal tumors and adenomas in ApcMin 
mice (5–8, 22). Therefore, we determined whether CXCL1 
expression correlates with PGE2 levels in CRCs (Fig. 1, B 
and C). The spearman rank coeffi   cient was used to test if the 
correlation was signifi  cant in all 16 paired samples. A positive 
correlation of PGE2 and CXCL1 was found in these samples 
(r = 0.37, P = 0.019). Similarly, analysis by quantitative 
PCR revealed that expression of mouse CXCL1 homologues 
MIP-2 and KC are much higher in intestinal adenomas than 
normal matched tissues in ApcMin mice (Fig. 1, D and E). To 
our knowledge, this is the fi  rst report that CXCL1 expression 
is increased in CRC and that it correlates with PGE2 levels.
CXCR2 expression is elevated in CRC
To establish the importance of CXCL1 in the CRC, we de-
termined whether its receptor, CXCR2, is also elevated in 
human tumors. Analysis of real-time quantitative PCR shows 
that CXCR2 expression is elevated in 11 of 16 (69%) cancer 
specimens (Fig. 2 A) and in all intestinal adenomas of ApcMin 
mice we tested (Fig. 2 B). Furthermore, we examined cell-
specifi  c expression of CXCL1 and its receptor CXCR2 in 
human colorectal carcinomas using immunohistochemistry. 
As shown in Fig. 2 C, intense staining for CXCL1 in epithe-
lial and stromal cells was observed in tumor tissues but not 
in matched normal tissues (Fig. 2 C, top), demonstrating that 
CXCL1 localizes to epithelial and stromal compartments of 
solid tumors. Strong CXCR2 immunostaining was also ob-
served only in human tumor biopsies and not in matched 
normal samples (Fig. 2 C, middle). Interestingly, CXCR2 
was expressed mainly in stromal endothelial cells as verifi  ed 
by staining with CD31 (Fig. 2 C, middle and bottom). These 
results indicate that CXCL1 secreted from human tumor epi-
thelial cells may promote tumor-associated angiogenesis by 
binding to CXCR2 expressed on endothelial cells.
PGE2 stimulates production of CXCL1
To determine whether PGE2 up-regulates CXCL1 and other 
angiogenic factors in CRC cells, a commercially available 
  antibody array of pro-angiogenic factors was used. The array 
Figure 2.  CXCR2 expression is elevated in human colorectal 
  tumors and adenomas of Apcmin mice. (A and B) The CXCL1 mRNA in 
human tumor samples listed above (A) and mouse intestinal adenoma 
tissues (B) were analyzed by quantitative real-time PCR. (C) Sections of 
formalin-fi  xed and paraffi  n-embedded tissues from 16 paired human 
tumors and the matched normal tissues were immunostained with anti-
CXCL1 (top), anti-hCXCR2 (middle), or anti-CD31 antibody. A set of repre-
sentative images is shown. Bar, 150 μm.944  PGE2 INDUCES CXCL1 EXPRESSION IN CRC CELLS | Wang et al.
was incubated with conditioned medium taken from LS-
174T cells treated with either vehicle or PGE2. By comparing 
the signal intensities, elevation of CXCL1 was seen in media 
obtained from LS-174T cells treated with PGE2 (Fig. 3 A). 
A quantitative PCR assay was performed to show that PGE2 
induced CXCL1 mRNA levels in three additional colorectal 
carcinoma cell lines and one breast cancer cell line (Fig. 3 B). 
Because LS-174T and HCA-7 cell lines have been exten-
sively used to investigate PGE2-dependent tumorigenesis, we 
further examined whether PGE2 could regulate CXCL1 pro-
moter activity and protein secretion in these two cell lines. 
Compared with the control cells, PGE2-treated LS-174T cells 
showed an increase in both CXCL1 promoter activity (Fig. 
3 C) and CXCL1 protein secretion (Fig. 3 D). The induction 
of CXCL1 was dependent on PGE2 concentration (Fig. 3, 
C and D). Similar results were observed in HCA-7 cells (not 
depicted). Collectively, these results demonstrate that PGE2 
up-regulates CXCL1 transcription, expression, and release, 
establishing a link between a proinfl  ammatory lipid mediator 
and a pro-angiogenic chemokine.
PGE2 induction of CXCL1 involves the EGFR–MAPK cascade
Because PGE2 can activate both the MAPK and PI3K–Akt 
pathways through EP4-EGFR receptor activation in LS- 
174T cells (23, 24), we investigated potential signaling 
  pathways aff  ected by PGE2 that contribute to the regulation 
of CXCL1. Pretreatment of LS-174T cells with a specifi  c 
MAPK inhibitor or EGFR tyrosine kinase inhibitor (Erlo-
tinib, OSI774) blocked PGE2-induced CXCL1 promoter 
activity and protein expression, respectively, whereas a spe-
cifi  c PI3K inhibitor (LY294002) had no eff  ect (Fig. 4). These 
data suggest that an EGFR-MAPK pathway is involved in 
the induction of CXCL1 by PGE2.
The supernatants from PGE2-treated CRC cells induce 
endothelial migration and tube formation
Migration of endothelial cells and assembly into tubes are two 
critical steps in tumor-associated angiogenesis. Because the 
conditioned medium from COX-2–overexpressing CRC cells
stimulates both endothelial migration and tube formation 
(25), we assessed whether PGE2 mediates tumor-associated 
angiogenesis. As shown in Fig. 5 A, the supernatants from 
PGE2-treated LS-174T CRC cells induced the migra-
tion of mouse endothelial cells (Py-4-1) and bovine lung 
  micro  vascular endothelial cells (BLMVECs). Furthermore, 
LS-174T–conditioned media enhanced the formation of ex-
tensive capillary-like structures in vitro (Fig. 5 B). Quantita-
tive evaluation of tube formation revealed that conditioned 
media from PGE2-treated cells increased the intersection 
number of tubular structures by one- to threefold in Py-4-1 
and BLMVECs, respectively (Fig. 5 C). Importantly, PGE2 
also induced CXCR2 expression in Py-4-1 cells (Fig. 5 D), 
suggesting that CXCL1 mediates the downstream eff  ects of 
PGE2 on endothelial cells. A similar result was observed in 
BLMVECs (not depicted). Two potential mechanisms that 
could explain the ability of PGE2 to enhance endothelial cell 
Figure 3.  PGE2 promotes CXCL1 expression and release. (A) Human 
antibody array analysis was used to determine the differences in the re-
lease of human angiogenic factors from the conditioned medium of LS-
174T cells treated with vehicle (left) or PGE2 (right). The positive controls 
produced by biotin-conjugated IgG can be used to compare the relative 
expression levels among the different membranes. (B) Quantitative real-
time PCR analysis of the mRNA level of CXCL1 in four CRC cell lines and 
one breast cancer cell line. The cells were incubated in serum-free media 
for 24 h and treated with 1 μM PGE2 for 4 h. The relative expression of 
target gene is averages of triplicates that are normalized against the tran-
script levels of hActin. Data are represented as the mean ± SE of the 
relative expression from three independent experiments. Asterisks repre-
sent statistical differences (P < 0.05; Student’s t test). (C) PGE2 stimulates 
CXCL1 promoter activity. The LS-174T cells were transiently transfected 
with CXCL1 (−306 to +45) luciferase reporter gene and pRL-SV40 plas-
mids followed by treatment with PGE2 for 24 h. The dual luciferase assays 
were performed as described in Materials and methods. Data are repre-
sented as the mean ± SE of relative luciferase activity from three inde-
pendent experiments. (D) The levels of CXCL1 protein in cell supernatants 
were determined by ELISA. Bar graphs show the values of CXCL1 concen-
tration in the conditioned medium of LS-174T cells treated with indicated 
amounts of PGE2 for 24 h, adjusted for cell number. Three independent 
experiments in duplicate were performed.JEM VOL. 203, April 17, 2006  945
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migration and tube formation were considered: (a) PGE2 
directly stimulates endothelial cell migration and tube for-
mation; or, (b) PGE2 stimulates CRC cells to produce pro-
angiogenic factors that then aff  ect endothelial cell biology. 
Our studies demonstrated that exogenous PGE2 alone in se-
rum-free medium failed to induce endothelial cell migration 
or tube formation (not depicted). Collectively, these results 
indicate that PGE2 enhances microvascular endothelial cell 
migration and tube formation.
CXCL1 is required for PGE2-mediated stimulation 
of endothelial cell migration and tube formation
We next investigated whether CXCL1 mediates the eff  ects 
of PGE2-induced endothelial cell migration and tube forma-
tion. We found that treatment with a CXCL1 neutralizing 
  antibody inhibited Py-4-1 cell migration induced by the 
conditioned media taken from PGE2-treated LS-174T cells 
(Fig. 6 A) or PGE2-treated HCA-7 cells (Fig. 6 B). Similarly, 
the CXCL1 neutralizing antibody also inhibited the migra-
tion of BLMVECs induced by treatment with conditioned 
  media (Fig. 6 C). We further examined whether CXCL1 
alone can induce endothelial cell migration. As shown in 
Fig. 6 D, human rCXCL1 also stimulated migration of 
both endothelial cell lines. Consistent with the observations 
  described above, blocking CXCL1 by adding a neutralizing 
antibody also completely inhibited Py-4-1 endothelial tube 
formation induced by treatment with conditioned media from 
LS-174T (Fig. 6 E) or HCA-7 (Fig. 6 F) cells. Furth  ermore, 
the observation that CXCL1 mediates Py-4-1 tube formation 
was confi  rmed in BLMVECs as well (Fig. 6 G). These results 
demonstrate that CXCL1 produced by PGE2-treated CRC 
cells can regulate angiogenesis in this in vitro model.
CXCL1 mediates the effect of PGE2 to stimulate tumor 
growth and increase microvessel density
To determine whether PGE2-induced CXCL1 regulates 
tumor growth or tumor-associated angiogenesis in vivo, 
female Rag2−/−/γc−/−/Flk1+/−lacZ triple mutant mice were 
Figure 4.  PGE2–up-regulated CXCL1 expression is dependent on 
MAPK pathway. (A) The effects of a MAPK inhibitor on PGE2–up-
  regulated CXCL1 promoter activity. The LS-174T cells were cultured and 
treated in the same conditions as noted in Fig. 3 C. The cells were pre-
treated with vehicle or increasing doses of inhibitors for 1 h before the 
PGE2 (1 μM) treatment after transfection. Data are represented as the 
mean ± SE of fold induction from three independent experiments. (B) The 
effects of a MAPK inhibitor on CXCL1 protein expression. LS-174T cells 
were cultured and treated as described in A. CXCL1 levels in cell superna-
tants were determined by ELISA. Data are represented as the mean ± SE 
of fold induction from three independent experiments. Figure 5.  Supernatants from LS-174T cells treated with PGE2 in-
duce endothelial migration and tube formation. (A) Cell movement 
was evaluated by counting the number of cells that migrated toward 
conditioned medium in the undersurface of the fi  lter. The data were rep-
resented as the mean ± SE of cell numbers of three independent experi-
ments performed in triplicate. (B and C) The Py-4-1 cells (top) and 
BPMVECs (bottom) form capillary-like structures on growth factor–
  reduced Matrigel in vehicle- or 1 μM PGE2-treated conditioned media (B). 
The number of the intersections between branches of assembled endothe-
lial cell networks was counted in whole fi  eld. Data were represented as 
the mean ± SE of intersection numbers of three independent experi-
ments (C). Asterisks represent statistical differences (P < 0.05; Student’s 
t test). (D) Quantitative real-time PCR analysis of the levels of CXCR2 
mRNA in LS-174T and Py-4-1 cell lines was performed.946  PGE2 INDUCES CXCL1 EXPRESSION IN CRC CELLS | Wang et al.
generated by crossing the heterozygous Flk1 female mice 
(Flk1+/−lacZ) to mutant males (Rag2−/−/γc−/y) and engrafting 
with human LS-174T cells (see Materials and methods for 
a complete description of how these mice strains were 
  developed). The LS-174T cells were inoculated, and mice 
were treated with normal mouse IgG or anti-CXCL1 neu-
tralizing mouse antibody (100 μg/mouse). After tumor en-
graftment (4 d), mice were gavaged with vehicle or PGE2 
(300 μg/each mouse) twice daily and antibody treatment was 
administered every 2 d for 10 d. Tumor growth was recorded 
every 2 d for a period of 2 wk. We found that PGE2 treat-
ment alone promoted tumor growth (Fig. 7 A) and induced 
CXCL1 expression (Fig. 7 B). Tumor cells showed diff  use 
cytoplasmic staining (brown) for CXCL1 (Fig. 7 B, top). 
Moreover, immunohistochemical staining was performed to 
determine whether CXCR2 receptors were present on the 
microvessels in these tumors. As shown in Fig. 7 B (bottom), 
CXCR2 was expressed on the endothelial cells in tumor 
microvessels and PGE2 treatment enhanced CXCR2 ex-
pression levels. In addition, PGE2-treated tumors exhibited 
a 2.6-fold higher density of lacZ-stained blood vessels than 
vehicle-treated tumors (Fig. 7 C). Similar to our observa-
tions in vitro, tumor growth and angiogenic response after 
PGE2 treatment was inhibited by administration of a CXCL1 
neutralizing antibody (Fig. 7, A and C). Because CXCL1 is 
known to stimulate melanoma cell proliferation, it is possible 
that tumor growth in our studies could depend on the ability 
of CXCL1 to induce LS-174T cell proliferation. However, 
we observed that CXCL1 failed to stimulate LS-174T cell 
proliferation in   vitro, even in suboptimal conditions (serum 
deprivation; not depicted). This is not surprising because 
LS-174T cells do not express the CXCL1 receptor, CXCR2 
(Fig. 5 D). Collectively, these results suggest that PGE2 pro-
motes tumor growth indirectly by inducing CXCL1 expres-
sion, which in turn stimulates angiogenesis.
DISCUSSION
It is well established that high COX-2 enzyme levels correlate 
with poor clinical outcome in cancer patients (26–32), and 
inhibition of cyclooxygenase is an eff  ective approach to re-
duce polyp burden in humans (33). Moreover, genetic studies 
demonstrate that colorectal tumor growth and vas  cular den-
sity are signifi  cantly attenuated in COX-2−/− null ApcMin mice 
(34), indicating that COX-2 plays a crucial role in tumor-as-
sociated angiogenesis (35, 36). Our laboratory demonstrated 
previously that overexpression of COX-2 in CRC cells stim-
ulates endothelial cell migration and tube formation when 
endothelial cells were cocultured with CRC cells express-
ing COX-2 (25). However, all of the mechanisms by which 
COX-2 stimulates angiogenesis are not known. In this study, 
we extended our previous work to assess the role of COX-
2–derived PGE2 in vitro and in vivo in tumor-associated
angiogenesis. We identifi   ed CXCL1 as a key downstream 
  mediator of PGE2 in regulating tumor-associated angiogenesis. 
We have established a role for CXCL1 in colorectal tumor–
associated angiogenesis by our results demonstrating reduced 
tumor growth and decreased tumor vascular density in mice 
treated with a neutralizing CXCL1 antibody. These fi  ndings
may have clinical relevance because CXCL1 is elevated in 
the majority of human CRCs and correlates well with tissue 
Figure 6.  CXCL1 mediates the effects of PGE2 on endothelial 
  migration and tube formation. (A–C) The effects of CXCL1 neutralizing 
antibody on endothelial migration. The Py-4-1 cells (A and B) or BPMVCs 
(C) were cultured and treated in the same conditions as noted in Fig. 4 A. 
The supernatants from LS-174T cells (A or C) or HCA-7 cells (B) were pre-
treated with either 5 μg of normal mouse IgG or anti-hCXCL1 mouse 
monoclonal antibody for 1 h before being placed in the lower chamber. 
The data were represented as the mean ± SE of cell numbers of three 
independent experiments performed in triplicate. (D) Recombinant CXCL1 
induces endothelial cell migration. The Py-4-1 cells and BPMVCs were 
cultured and treated in the same conditions as noted in Fig. 4 A. The 
  serum-free DMEM medium with indicated amounts of CXCL1 was placed 
in the lower chamber. The data were represented as the mean ± SE of cell 
numbers of three independent experiments performed in triplicate. (E–G) 
The effects of CXCL1 neutralizing antibody on endothelial tube formation. 
The Py-4-1 cells (E and F) and BPMVCs (G) were cultured and treated 
in the same conditions as noted in Fig. 4 B. The supernatants from LS-174T 
(E and G) or HCA-7 (F) cells were pretreated with either 5 μg of normal 
mouse IgG or anti-hGROα mouse monoclonal antibody for 1 h before 
being placed in the lower chamber. Data were represented as the mean ± SE 
of intersection numbers of three independent experiments.JEM VOL. 203, April 17, 2006  947
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PGE2 levels. Importantly, this study delineates a novel 
  molecular mechanism by which COX-2 regulates tumor-
associated angiogenesis.
The molecular events involved in progression of CRC 
are complex, involving dysregulation of factors that regulate 
cell growth and cell death, evasion of host defenses, invasion, 
and metastasis. Tumor growth and metastatic spread of dis-
ease are dependent on angiogenesis (37–40), and substantial 
increases in tumor size require a dependable blood supply. 
For neoplasms to develop a stable blood supply, the tumor 
cells and/or the stromal microenvironment must secrete a va-
riety of pro-angiogenic factors, including vascular endothelial 
growth factor (VEGF) and CXC chemokines that stimulate 
endothelial cell proliferation, migration, and tube formation 
(19–21, 25, 41–44). Inhibition of tumor-associated angio-
genesis is being pursued as a promising therapeutic strategy 
for treatment of patients with advanced disease. Recently, 
Avastin (bevacizumab), which blocks VEGF signaling, was 
approved for treatment of patients with advanced CRC. 
However, treatment with bevacizumab plus chemotherapy 
extends progression-free survival in patients with metastatic 
CRC by only 5–10 mo (45, 46), and this treatment is very 
expensive. ELISA analysis revealed that LS-174T cells do se-
crete VEGF at very low levels compared with the amount of 
CXCL1 (Fig. S1 A, available at http://www.jem.org/cgi/
content/full/jem.20052124/DC1, and Fig. 3 D). Therefore, 
it is crucial to determine what other pro-angiogenic factors 
are involved in progression of CRC. Our in vitro and in vivo 
results here demonstrate that CXCL1 is an important target 
for PGE2 signaling in CRC cells (Figs. 3 and 7 B).
Although our studies support the role of CXCL1 as an 
important angiogenic factor in tumor growth, other angio-
genic factors are likely to be involved as well. For example, 
we were unable to fully inhibit basal tumor–associated an-
giogenesis by only targeting CXCL1 (Fig. 7 C). Moreover, 
the ability of CXCL1 alone to induce cell migration is less 
than that seen with conditioned media (Fig. 6 D), indicating 
that CXCL1 is not the sole factor involved in the regula-
tion of endothelial cell migration. One plausible explanation 
is that human CRC cells in vivo produce other members 
of the CXC chemokine family, bFGF, and VEGF, which 
also promote neovascularization. For example, recombinant 
hVEGF stimulated endothelial cell migration in both Py-4-1 
and BLMVECs (Fig. S1 B), although the ability of VEGF 
alone to induce cell migration is much less than that seen 
with conditioned media. However, VEGF failed to synergize 
with CXCL1 on stimulating endothelial cell migration in our 
in vitro model (Fig. S1 C). It is possible that VEGF may 
synergize with CXCL1 to further stimulate angiogenesis in 
vivo. Further work is needed to determine whether both an-
giogenic factors coordinate tumor-associated angiogenesis in 
vivo. We have performed real-time quantitative PCR assays 
to determine whether VEGF levels correlate with CXCL1 in 
human tumor samples. As shown in Fig. S1 E and Fig. 1 A, 
VEGF expression is elevated in 17 of 20 (85%) cancer speci-
mens and positively correlates with CXCL1 expression (r = 
0.65, P < 0.0001). In this study, we demonstrate that PGE2 
accelerates tumor growth, in part, by inducing CXCL1 se-
cretion by tumor epithelial cells. These results may point out, 
in part, why treating patients with only one anti-angiogenic 
agent may not be the most eff  ective clinical regimen.
Chemokines and their respective receptors are classifi  ed 
into the CXC, CC, C, and CX3C families based on the po-
sitions of their conserved two NH2-terminal cysteine resi-
dues. Although chemokines play a crucial role in immune 
Figure 7.  Blocking CXCL1 inhibited PGE2-enhanced tumor growth 
and angiogenesis. (A) The effect of PGE2 and anti-CXCL1 antibody on 
human colorectal xenograft tumor growth. The Rag2−/−/γc−/−/Flk1+/−lacZ 
mice were cotreated with a combination of vehicle and normal mouse IgG 
(n = 6), PGE2 and normal mouse IgG (n = 6), or PGE2 and anti-GROα 
(n = 6) as described in Materials and methods. (B) PGE2 up-regulates 
CXCL1 expression in xenografted tumors. Sections from each group were 
immunostained with anti-CXCL1 (top) or anti-mCXCR2 (bottom) antibody. 
A representative section shows strong diffuse cytoplasmic staining 
(brown) for CXCL1 in the tumor cells taken from mice treated with PGE2. 
Faint staining was observed in the tumor cells of vehicle-treated mice. In 
addition, a positive signal is visible when evaluating tumor microvessels. 
Bar, 50 μm. (C) lacZ-stained tumor blood vessels in Rag2−/−/γc−/−/Flk1+/−lacZ 
mice after PGE2 treatments. Photomicrographs of lacZ staining of repre-
sentative tissue-sections are shown. Results were presented as the mean 
of vessel number ± SEM per fi  eld. Bar, 300 μm. A total of 120 fi  elds were 
examined and counted from six tumors of each group. Four sections from 
six mice in each group were evaluated for quantifi  cation of lacZ staining. 
Results are as mean ± SEM. Values were statistically signifi  cant from 
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and infl  ammatory reactions, such as allergic disorders, auto-
immune diseases, and viral infections, recent studies indicate that 
they have an equally important role in the development of a 
variety of cancers, such as melanomas, ovarian, breast, lung, and 
prostate cancers (47). Some of these chemokines are involved 
in transformation, survival, growth, metastasis, and angiogenesis.
The chemokine receptors expressed on tumor cells may con-
tribute to organ-specifi   c metastasis. For example, CXCR4 
is expressed and participates in directed migration of cancer 
cells to sites of metastasis in many cancers, including small cell 
lung cancer, pancreatic cancer, astrogliomas, myelomas, B cell 
lymphomas, and chronic lymphocytic leukemias (48). More-
over, tumor cells and/or stromal cells produce infl  ammatory 
  chemokines, which in turn result in the recruitment of various 
types of leukocytes into the tumor tissue through binding to 
their receptors expressed on these leukocytes. These infi  ltrat-
ing leukocytes in tumors promote neoplastic development. In 
breast cancer, it has been shown that macrophage infi  ltration 
promotes tumor invasion and metastasis (49).
PGE2 inhibits production of CC chemokines CCL3 
(MIP-1α) and CCL4 (MIP-1β) in dendritic cells through 
binding to the EP2 receptor (50, 51) and suppresses CC 
chemokine CCL5 (RANTES [regulated upon activation, 
normal T cell expressed and secreted]) production in human 
macrophages through the EP4 receptor (52). Because breast 
cancer cells produce CCL5, we examined whether PGE2 
regulates these CC chemokines in CRC cells. Analysis of 
real-time quantitative PCR revealed that PGE2 up-regulated 
expression of CCL3, CCL4, and CCL5 in LS-174T cells 
(Fig. S1 D). These CC chemokines are crucial for macro-
phage and lymphocyte infi  ltration in human breast, cervix, 
pancreas, and gliomas cancers (53, 54). These results indicate 
that PGE2 promotes tumor growth and metastasis through, in 
part, by recruiting these macrophages and lymphocytes into 
tumor tissues. Moreover, a recent study showed that COX-2 
up-regulates expression of CXC chemokines such as CXCL5 
(epithelial cell–derived neutrophil activator 78) and CXCL8 
(IL-8) in human non-small cell lung cancer cells (55), indi-
cating that PGE2 can regulate the expression of CXC che-
mokines in certain contexts. In this study, we present a novel 
mechanism by which PGE2 stimulates expression of the CXC 
chemokine CXCL1 in CRC cells through activation of an 
EGFR–MAPK cascade (Fig. 3 and 4). Because our previous 
results showed that PGE2 can transactivate EGFR through 
activation of EP4 receptor signaling in LS-174T cells (23), it 
is likely that the EP4 mediates the eff  ects seen on the EGFR–
MAPK signaling cascade.
Recent evidence demonstrates that CXCR2 is expressed 
in intestinal microvessels (56) and other endothelial cells, 
such as lung microvascular endothelial cells, dermal micro-
vascular endothelial cells, umbilical vein endothelial cells, 
and saphenous vein endothelial cells (57). Moreover, inhi-
bition of COX-2 by nonselective or selective nonsteroidal 
antii  nfl  ammatory drugs suppresses αVβ3-mediated Cdc42/Rac-
depenent migration and spreading of endothelial cells (58). 
Interestingly, PGE2 promotes αVβ3-Cdc42/Rac-dependent 
migration and spreading of endothelial cells (59). There is 
strong evidence indicating that CXCL1 can promote Rac/
cdc42-Pak1–dependent migration via the CXCR2 receptor 
(60). Thus, it is possible that the Rac/cdc42-Pak1 cascade is 
required for CXCL1-induced endothelial cell migration and 
tube formation. Further studies are needed to address these 
issues more completely.
The biological signifi  cance of the PGE2-induced CXCL1 
expression and secretion in CRC cells was substantiated by 
the results of our in vivo experiments. Administration of ex-
ogenous PGE2 promoted tumor growth and increased micro-
vessel density. Inhibition of PGE2-induced CXCL1 signaling 
led to inhibition of tumor growth with decreased microvessel 
density (Fig. 7). One very interesting fi  nding from both our 
in vitro and in vivo experiments is that CXCL1 expression 
correlates with PGE2 levels in human CRCs (Fig. 1).
The key fi  nding of this study is that PGE2 stimulates tu-
mor epithelial cells to secrete the pro-angiogenic chemokine 
CXCL1 via activation of the EP4-EGFR–MAPK cascade. 
Furthermore, we reveal the importance of PGE2–up-regu-
lated CXCL1 in tumor-associated angiogenesis. To our 
knowledge, this represents the fi  rst report suggesting that 
the up-regulation of CXCL1 is directly involved in the pro-
angiogenic eff  ects of PGE2 in CRC.
MATERIALS AND METHODS
Cell culture and reagents. LS-174T, HCA-7, HCT-15, CaCo-2, and 
MCF-7 cells were maintained in McCoy’s 5A medium with 10% FBS (Hy-
clone). BLMVECs (VEC Technologies) were maintained in EGM medium 
(Cambrex Corp.) with 5% FBS. A mouse endothelial cell line (Py-4-1) es-
tablished from hemangiomas of adult transgenic mice carrying the Py virus 
early region transgene was cultured in 1.5% gelatin-coated plates with 
DMEM medium with 10% FBS. PD98059 and LY 294002 were obtained 
from Calbiochem. OSI 774 was provided by Genentech, Inc.
CXCL1 and ELISA. CXCL1 production from cell-free supernatants and 
tissues was measured by using a human CXCL1 Quantikine ELISA kit (R&D 
Systems) according to the manufacturer’s instructions. In brief, 0.5 × 106 
LS-174T cells were cultured in serum-free medium for 16 h and pre-
treated  with indicated inhibitors for 1 h. After pretreatment, cells were 
treated with vehicle or indicated concentration of PGE2 for 24 h. The se-
rum-free conditioned media was subjected to ELISA assay. For human 
  tumor and normal tissues, total proteins were extracted by homogenizing 
and subsequently sonicating in anti-protease buff  er (50 mM Hepes, 150 mM 
NaCl, and 1 mM EDTA) with protease inhibitor cocktail tablets (Boehringer). 
With Vanderbilt University Internal Review Board approval, human 
  colorectal tumor and matching normal mucosa specimens were obtained 
from surgical resections.
PGE2 levels. Human colorectal tumor and matched normal tissues were 
homogenized, and PGE2 was acidifi  ed and extracted from the homogenate as 
described previously (61). The levels of PGE2 in the tissue were quantifi  ed us-
ing gas chromatography negative ion chemical ionization mass spectrometry as 
described previously (61). The concentration of PGE2 in the samples was cal-
culated by comparing the ratios of its peak areas with the internal standard.
Real-time quantitative PCR. CXCL1, MIP-2, KC, hCXCR2, and 
mCXCR2 mRNA was quantifi  ed by real-time quantitative PCR using 
iCycler (Bio-Rad Laboratories) and iQ SYBR Green Supermix (Bio-Rad 
Laboratories). In brief, total RNA was isolated using TRIzol Reagent 
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reverse transcribed using SuperScript II RT kit (Invitrogen). The real-time 
PCR assay was conducted according to the manufacturer’s instructions. 
Primers for CXCL1, MIP-2, KC, and mGAPDH genes were chosen by us-
ing the computer program Beacon Designer 4. The sequences of the specifi  c 
PCR primers were as follows (5′ to 3′): hβ-actin, forward: A  G  A  A  A  A  T  C  T-
G  G  C  A  C  C  A  C  A  C  C  ; reverse: A  G  A  G  G  C  G  T  A  C  A  G  G  G  A  T  A  G  C  A  ; CXCL1, 
forward: A  A  C  C  G  A  A  G  T  C  A  T  A  G  C  C  A  C  A  C  ; reverse: G  T  T  G  G  A  T  T  T  G-
T  C  A  C  T  G  T  T  C  A  G  C  ;  hCXCR2, forward: A  A  C  A  T  G  G  A  G  A  G  T  G  A  C  A  G-
C  T  T  T  G  ; reverse: T  T  C  A  C  A  T  G  G  G  G  C  G  G  C  A  T  C  ;  mGAPDH, forward: 
G  C  C  T  T  C  C  G  T  G  T  T  C  C  T  A  C  C  C  ; reverse: T  G  C  C  T  G  C  T  T  C  A  C  C  A  C  C-
T  T  C  ;  mCXCR2, forward: G  T  G  C  A  T  A  G  C  C  A  T  G  T  G  G  T  T  A  C  ; reverse: 
G  G  C  A  G  G  A  T  A  C  G  C  A  G  T  A  C  G  ; MIP-2, forward: G  G  G  A  G  A  G  G  G  T  G  A  G-
T  T  G  G  G  ; reverse: G  C  A  C  A  C  T  A  C  T  T  C  C  A  T  G  A  A  A  G  C  ; and KC, forward: 
A  A  A  A  G  G  T  G  T  C  C  C  C  A  A  G  T  A  ; reverse: A  A  G  C  A  G  A  A  C  T  G  A  A  C  T  A  C  C-   
A  T  C  G  . Relative signal intensity (CXCL1/β-actin, hCXCX2/β-actin, MIP-2/
GAPDH, KC/GAPDH, and mCXCR2/GAPDH) was measured and used 
for quantifi  cation.
Human angiogenesis antibody array. Pro-angiogenic protein levels 
from cell-free supernatants were determined by using the RayBio Human 
Angiogenesis Antibody Array I (RayBiotech Inc.) according to the manu-
facturer’s instructions. In brief, 0.5 × 106 LS-174T cells were cultured in se-
rum-free medium for 16 h and treated with vehicle or PGE2 for 24 h. The 
membranes were exposed to a blocking buff  er, and 1 ml of the conditioned 
media from cells was then treated with either vehicle or PGE2. The mem-
branes were washed and incubated by primary biotin-conjugated antibody. 
The membranes were then incubated with horseradish peroxidase–
  conjugated streptavidin, and the protein spots were detected using the ECL 
Western blotting detection reagents (GE Healthcare) according to the man-
ufacturer’s instructions.
Transfection and reporter activity assay. CXCL1 promoter reporter 
constructs were obtained from A. Richmond (Vanderbilt University, Nash-
ville, TN) as described previously (62). The LS-174T cells (2.0 × 105) were 
transiently cotransfected with 0.4 μg CXCL1 (−306 to +45) and 5 ng 
pRL-SV40 plasmids using LipofectAMINE Plus reagent according to the 
manufacturer’s instructions (Life Technologies). After incubation for 3 h, 
fresh serum-free media was added and the cells were incubated for an addi-
tional 4 h. The cells were then pretreated with inhibitors as indicated for 1 h 
and treated with either vehicle or/and PGE2 for 24 h. Luciferase activity was 
measured using a Dual Luciferase kit (Promega) with a Monolight 3010 lu-
minometer (BD Biosciences). The relative luciferase activity was determined 
and normalized to Renilla luciferase.
Migration assays. Migration assays were performed using transwells 
(6.5 mm in diameter and 8-μm pore size; Corning Costar Co.) as described 
  previously (24). After a 24-h incubation in serum-free DMEM medium, cells 
(4 × 104/well) were suspended in 400 μl of serum-free DMEM medium and 
placed in the upper chamber. The lower chamber was fi  lled with 1 ml of the 
conditioned media from LS-174T or HCA-7 cells treated with vehicle or 
PGE2. For antibody studies, the supernatants from both cells were pretreated 
with either 5 μg of normal mouse IgG or anti-CXCL1 mouse monoclonal 
antibody (R&D Systems) for 1 h. The supernatants were then placed in the 
lower chamber. For recombinant CXCL1 studies, the serum-free DMEM 
medium with indicated amounts of CXCL1 was placed in the lower chamber.
After 24 h at 37°C, the cells on the upper surface of the fi  lter were removed. 
The fi  lters were fi  xed and stained with 0.5% crystal violet solution. Cells 
adhering to the undersurface of the fi  lter were counted, and the data were 
represented as the mean ± SE of cell numbers of three independent exper-
iments in triplicate.
In vitro vascular assembly assays. In vitro vascular assembly assays were 
performed as described previously (25). Transwells (12 mm in diameter and 
0.4-μm pore size; Corning Costar Co.) were coated with 100 μl of growth 
factor–reduced Matrigel (BD Biosciences). After 24 h in OPTI-MEM I 
  Reduced-Serum Medium (Life Technologies), 1.4 × 104 BPMVECs or 
3 × 104 Py-4-1 cells were plated in wells, respectively. The lower chamber 
was fi  lled with 1 ml of the conditioned media from LS-174T or HCA-7 
cells treated with vehicle or PGE2. For antibody studies, the supernatants 
from both cell lines were pretreated with either 5 μg of normal mouse IgG 
or anti-CXCL1 mouse antibody for 1 h. After incubation for 12 h for Py-
4-1 cells or 16 h for BMMVECs, tube-like structures were quantifi  ed by 
counting the number of intersections between branches of endothelial cell 
networks in whole fi  eld. Values were represented as the mean ± SE of in-
tersection numbers of three independent experiments.
Allograft tumor growth. Rag2−/− knockout mice have been developed 
that express no T and B lymphocytes, whereas Rag2(−/−)/IL-2Rγ−/− (com-
mon γ-chain [γc]) double knockout mice (Rag2(−/−)/γc(−/−)) completely 
lacked T and B lymphocytes and natural killer cells. It has been reported that 
Rag2−/−/γc−/− mice accepted the grafts at the greatest rate as compared 
with SCID and Rag2−/− mice (63). The heterozygous Flk1 female mice 
(Flk1+/−lacZ) were bred to mutant males (Rag2(−/−)/γc(−/y), homozygous for 
Rag2 and hemizygous null for the γc). The heterozygous female off  spring 
(Rag2+/−/γc+/−/Flk1+/−lacZ) were identifi  ed by PCR with allele-specifi  c 
primers. These females were then mated back to mutant males (Rag2−/−/
γc−/y) to obtain Rag2−/−/γc+/y/Flk1+/−lacZ male mice. The males were 
then bred back to the Rag2+/−/γc+/− female mice to generate triple mutant 
female mice (Rag2−/−/γc−/−/Flk1+/−lacZ) and male mice (Rag2−/−/γc−/y/
Flk1+/−lacZ). The colony (Rag2−/−/γc−/−/Flk1+/−lacZ) has been established at 
our facility by crossing triple mutant female mice (Rag2−/−/γc−/−/Flk1+/−lacZ) 
with triple mutant male mice (Rag2−/−/γc−/y/Flk1+/−lacZ). PCR analysis 
of tail genomic DNA was used to determine the genotypes.
LS-174T cells were used for tumor growth studies in vivo. A suspension 
of 2.5 × 106 LS-174T cells in 0.1 ml PBS was placed under the back skin 
of 7–8-wk-old female Rag2−/−/γc−/−/Flk1+/−lacZ mice. The mice (n = 18) 
were randomly placed into three groups according to the PGE2 and anti-
CXCL1 antibody treatment regimen (vehicle/100 μg normal mouse IgG/
each mouse, 300 μg PGE2/100 μg normal mouse IgG/each mouse, and 
300 μg PGE2/100 μg anti-CXCL1/each mouse). The mice were injected with
either normal mouse IgG or anti-CXCL1 neutralizing mouse antibody every 
2 d via intraperitoneal administration. The animals were maintained under 
sterile conditions in laminar fl  ow rooms, and tumors were measured every 
2 d by direct measurement of tumor volume in groups of six. After tumor 
engraftment (4 d), these mice were gavaged with the vehicle or PGE2 twice 
a day for 10 d. Tumor volume was determined by external measurement and 
calculated according to the equation (V = 0.5 × [LW2]), where V = volume, 
L = length, and W = width. A portion of the tumor was fi  xed in 0.2% 
  paraformaldehyde for lacZ staining and immunohistochemical staining.
lacZ staining and quantifi  cation. The expression of β-galactosidase was 
assessed by lacZ staining as described previously (64). Small pieces of tissue 
were fi  xed in 0.2% paraformaldehyde solution followed by infusion in 30% 
sucrose at 4°C overnight. Tissues were embedded in OCT and snap-frozen. 
Frozen sections were mounted onto glass slides and stained overnight at 
37°C using 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside as a sub-
strate. Sections were counterstained with eosin. The number of lacZ-stained 
blood vessels in tumor tissues was quantitated. Random sections of tumor 
tissues were used for lacZ staining, and measurements were made using the 
Scion Image program (Scion Corp.). Any distinct area of positive staining for 
lacZ (blue) was counted as a single vessel. Results were expressed as the 
mean number of vessels ± SEM per fi  eld (100×). 120 fi  elds were examined 
and counted from six tumors of each groups.
Immunohistochemical staining. 5-μm-thick tissue sections (n = 5 per 
animal) were stained with anti-CXCL1, mouse monoclonal antibody (R&D 
Systems), anti-hCXCR2, anti-CD31 (Santa Cruz Biotechnology, Inc.), and 
anti-mCXCR2 goat antibody at a dilution of 1:250. The immunohisto-
chemical staining was completed by using a Zymed-Histostain-SP kit 
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Online supplemental material. Fig. S1 A shows that PGE2 induces VEGF 
secretion. Fig. S1 B demonstrates that recombinant hVEGF stimulates endo-
thelial cell migration.  Fig. S1 C reveals that VEGF does not synergize with 
CXCL1 on inducing endothelial cell migration.  Fig. S1 D illustrates the 
ability of PGE2 to induce CC chemokines.  Fig. S1 E shows VEGF mRNA 
expression in human colorectal tumor and matched normal tissues. Fig. S1 is 
available at http://www.jem.org/cgi/content/full/jem.20052124/DC1.
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